Search

Search Results

• Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy

  Chiara Vassallo, Beatrice Canali, Francesca Fiorentino, Paolo Morelli, Silvia Ripoli, Laura Fioravanti

  103-109

  2023-10-02

  DOI: https://doi.org/10.33393/ao.2023.2609

• Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy

  Gian Luca Breschi, Federica Demma, Paolo Morelli, Maria De Francesco

  81-87

  2021-09-02

  DOI: https://doi.org/10.33393/ao.2021.2263

• Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy

  Francesca Fiorentino, Beatrice Canali, Paolo Morelli, Federica Demma

  6-12

  2023-01-16

  DOI: https://doi.org/10.33393/ao.2023.2486